Comparative Pharmacology
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus SODIUM PHOSPHATE P 32.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus SODIUM PHOSPHATE P 32.
SELENOMETHIONINE SE 75 vs SODIUM PHOSPHATE P 32
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
Sodium phosphate P 32 is a radioactive isotope that emits beta particles, causing ionization and subsequent cell death, particularly in rapidly dividing cells. It is incorporated into DNA and RNA, concentrating in tissues with high metabolic activity such as bone marrow and neoplastic cells.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
Intravenous administration: 1.5 mCi (55.5 MBq) per 70 kg body weight, single dose. For polycythemia vera, oral dose: 3-5 mCi (111-185 MBq) as a single dose. Frequency is one-time or as needed based on response.
None Documented
None Documented
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Terminal elimination half-life: 14.3 days (range 13-16 days). Clinically relevant for bone marrow suppression monitoring; cumulative effect over multiple doses.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Renal: ~40% within 24 hours via glomerular filtration; Fecal: ~60% over 1-2 weeks as unabsorbed or secreted into bile. Total elimination approaches 100% after 2 weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical